Psychedelics biotech Mydecine Innovations Group (OTC:MYCOF) is advancing the development of its novel compounds family of next-gen MDMA analogs.
So far, Mydecine's compounds show promising pharmacokinetics (PK) and pharmacodynamics (PD) in preclinical models.
The new data on the MYCO-006 family shows "considerably" shorter half-life (a projected estimated 1 to 2 hours) and accelerated onset (four-fold is projected) while retaining MDMA's desirable features toward potentially treating PTSD, anxiety, depression, addiction and chronic pain.
This combination will "significantly improve" the compounds' potential use in already-existing medical and clinical settings versus new, specialized facilities. Clinicians can use the drugs to improve treatment efficacy while eliminating the need for further post-session patient monitoring. This is expected to reduce costs in terms of physician hours, the company said.
As such, Mydecine has filed several patent claims for these drug candidates covering composition of matter and granting a 20-years use exclusivity.
CEO Joshua Bartch stated the company is confident MAPS will receive FDA clearance for MDMA this year, following the compound's demonstrated much higher efficacy rates than existing treatments for PTSD and other indications.
Bartch says "Gen-1" MDMA therapy might come with "serious flaws" such as not being able to offer the medicine in the current medical infrastructure — something that would provide access to "a substantially larger proportion of the suffering population" as well as "significantly increase the volume of treatments."
ICYMI, exclusive coverage from the Benzinga Psychedelics Capital Conference 2023:
-
Johns Hopkins Professor: Psychedelic Medicine Could Get Messy, Calls For 'Right, Smart, Non-Restrictive, Yet Preventive' Regulations
-
Investing In The Unique Growth Market Of Psychedelics
-
MDMA Therapy Experts Debate Upcoming Approval, Psychedelic Market Opps
-
Ketamine Therapy Leaders Share Bold Vision For Future Of Psychedelics
-
In Reinventing Mental Health & Next-Gen Psychedelics, 'Access And Clinical Data Are Key'
-
Fireside With Enveric Biosciences's Dr. Tucker, Unlocking Psychedelic Healing Benefits
-
Making The World A Better Place, How Psychedelics Are Helping
Photo: Benzinga edit with photo by Blue Planet Studio and ANDREI ASKIRKA on Shutterstock.